ADP-Rezeptor-Antagonisten: neue Erkenntnisse zur Therapie und Prophylaxe der ischämischen Herzerkrankung

Zusammenfassung

Adenosindiphosphat (ADP)-induzierte Plättchenaktivierung spielt eine entscheidende Rolle bei der Bildung des thrombotischen Gefäßverschlusses und der Pathogenese der koronaren Herzerkrankung. Die duale Thrombozytenaggregationshemmung mit den ADP-Rezeptor-Antagonisten wie Clopidogrel in Kombination mit Aspirin gilt inzwischen als Standardtherapie nach erfolgter Stentimplantation. Der vorliegende Beitrag gibt eine Übersicht über die aktuellen Entwicklungen auf dem Gebiet der ADP-Rezeptor-Antagonisten.

Abstract

Adenosine diphosphate (ADP)-induced platelet activation plays a pivotal role in the thrombocyte aggregation and pathogenesis of ischemic heart disease. The long-term benefit of dual anti-platelet therapy with ADP-receptor antagonists, such as clopidogrel, in combination with aspirin is well established for patients following coronary stent implantation. This review discusses latest developments in the field of ADP-receptor antagonists.

Schlüsselwörter

Thienopyridine - Ticagrelor - Cangrelor - akutes Koronarsyndrom

Keywords

thienopyridines - ticagrelor - cangrelor - acute coronary syndrome

Literatur

• 1 A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.  Lancet. 1996;  348 1329-1339
• 2 Angiolillo D J, Guzman L A. Clinical overview of promising nonthienopyridine antiplatelet agents.  Am Heart J. 2008;  156 S23-28
• 3 Banerjee S, Weideman R A, Weideman M W. et al . Effect of concomitant use of clopidogrel and proton pump inhibitors after percutaneous coronary intervention.  Am J Cardiol. 2011;  107 871-878
• 4 Bhatt D L, Cryer B L, Contant C F. et al . Clopidogrel with or without omeprazole in coronary artery disease.  N Engl J Med. 2010;  363 1909-1917
• 5 Bhatt D L, Lincoff A M, Gibson C M. et al . Intravenous platelet blockade with cangrelor during PCI.  N Engl J Med. 2009;  361 2330-2341
• 6 Brandt J T, Close S L, Iturria S J. et al . Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel.  J Thromb Haemost. 2007;  5 2429-2436
• 7 Brass L F, Manning D R, Cichowski K, Abrams C S. Signaling through G proteins in platelets: to the integrins and beyond.  Thromb Haemost. 1997;  78 581-589
• 8 Cannon C P, Husted S, Harrington R A. et al . Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: primary results of the DISPERSE-2 trial.  J Am Coll Cardiol. 2007;  50 1844-1851
• 9 Chen Z M, Jiang L X, Chen Y P. et al . Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial.  Lancet. 2005;  366 1607-1621
• 10 Farid N A, Payne C D, Small D S. et al . Cytochrome P450 3A inhibition by ketoconazole affects prasugrel and clopidogrel pharmacokinetics and pharmacodynamics differently.  Clin Pharmacol Ther. 2007;  81 735-741
• 11 Fischbach W, Darius H, Gross M. et al . [Concomitant use of platelet aggregation inhibitors and proton pump inhibitors (PPIs): Position paper of the German Society for Digestive and Metabolic Diseases (DGVS) and the German Society of Cardiology (DGK)].  Z Gastroenterol. 2010;  48 1156-1163
• 12 Fuster V, Badimon L, Badimon J J, Chesebro J H. The pathogenesis of coronary artery disease and the acute coronary syndromes (2).  N Engl J Med. 1992;  326 310-318
• 13 Gawaz M P. Das Blutplättchen. Stuttgart: Georg Thieme; 1999 23: 29-36
• 14 Gent M, Blakely J A, Easton J D. et al . The Canadian American Ticlopidine Study (CATS) in thromboembolic stroke.  Lancet. 1989;  1 1215-1220
• 15 Hass W K, Easton J D, Adams Jr H P. et al . A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. Ticlopidine Aspirin Stroke Study Group.  N Engl J Med. 1989;  321 501-507
• 16 Hechler B, Eckly A, Ohlmann P, Cazenave J P, Gachet C. The P2Y1 receptor, necessary but not sufficient to support full ADP-induced platelet aggregation, is not the target of the drug clopidogrel.  Br J Haematol. 1998;  103 858-866
• 17 Husted S, Emanuelsson H, Heptinstall S. et al . Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin.  Eur Heart J. 2006;  27 1038-1047
• 18 Jantzen H M, Gousset L, Bhaskar V. et al . Evidence for two distinct G-protein-coupled ADP receptors mediating platelet activation.  Thromb Haemost. 1999;  81 111-117
• 19 Janzon L, Bergqvist D, Boberg J. et al . Prevention of myocardial infarction and stroke in patients with intermittent claudication; effects of ticlopidine. Results from STIMS, the Swedish Ticlopidine Multicentre Study.  J Intern Med. 1990;  227 301-308
• 20 Lima J P, Brophy J M. The potential interaction between clopidogrel and proton pump inhibitors: a systematic review.  BMC Med. 2010;  8 81
• 21 Mega J L, Close S L, Wiviott S D. et al . Cytochrome p-450 polymorphisms and response to clopidogrel.  N Engl J Med. 2009;  360 354-362
• 22 Mega J L, Close S L, Wiviott S D. et al . Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes.  Circulation. 2009;  119 2553-2560
• 23 Mehta S R, Yusuf S, Peters R J. et al . Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.  Lancet. 2001;  358 527-533
• 24 Sabatine M S, Cannon C P, Gibson C M. et al . Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation.  N Engl J Med. 2005;  352 1179-1189
• 25 Sugidachi A, Ogawa T, Kurihara A. et al . The greater in vivo antiplatelet effects of prasugrel as compared to clopidogrel reflect more efficient generation of its active metabolite with similar antiplatelet activity to that of clopidogrel’s active metabolite.  J Thromb Haemost. 2007;  5 1545-1551
• 26 Wallentin L, Becker R C, Budaj A. et al . Ticagrelor versus clopidogrel in patients with acute coronary syndromes.  N Engl J Med. 2009;  361 1045-1057
• 27 Wang T H, Bhatt D L, Topol E J. Aspirin and clopidogrel resistance: an emerging clinical entity.  Eur Heart J. 2006;  27 647-654
• 28 Wiviott S D, Braunwald E, Angiolillo D J. et al . Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-Thrombolysis in Myocardial Infarction 38.  Circulation. 2008;  118 1626-1636
• 29 Wiviott S D, Braunwald E, McCabe C H. et al . Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the TRITON-TIMI 38 trial: a subanalysis of a randomised trial.  Lancet. 2008;  371 1353-1363
• 30 Wiviott S D, Braunwald E, McCabe C H. et al . Prasugrel versus clopidogrel in patients with acute coronary syndromes.  N Engl J Med. 2007;  357 2001-2015
• 31 Yusuf S, Zhao F, Mehta S R. et al . Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.  N Engl J Med. 2001;  345 494-502